)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Stevanato Group
Stevanato Group (STVN) investor relations material
Stevanato Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 revenue rose 8% to €326.1M, with 8.2% organic growth; BDS strength offset an Engineering decline.
Adjusted EBITDA increased 14% to €88.8M, with margin up 150 bps to 27.2%; FY2026 guidance was maintained.
Non-GLP-1 biologics grew over 30% in Q3; GLP-1s represented 17%–18% of revenue, with lower expected volumes temporarily moderating FY2027 growth.
Financial highlights
Revenue was €326.1M versus €303.2M; high-value solutions rose 1% to €149.4M, or 46% of total revenue.
Net profit increased 16% to €41.8M; diluted EPS was €0.15 versus €0.13. Adjusted net profit was €44.0M and adjusted diluted EPS was €0.16.
Adjusted EBITDA grew 14% to €88.8M; gross profit margin decreased 10 bps to 29.1%.
Outlook and guidance
FY2026 guidance reiterated: revenue €1.260B–€1.280B, adjusted EBITDA €335.0M–€345.2M and adjusted diluted EPS €0.60–€0.62; implied organic growth is 8%–10%.
BDS is expected to grow organically at a low-double-digit rate at the guidance midpoint; Engineering revenue is forecast at €124M–€134M.
FY2027 growth is expected to be low single digits as lower GLP-1 volumes temporarily moderate growth; biologics demand is expected to backfill most of the decline, with validation and ramp-up still needed.
Without the temporary GLP-1 headwind, growth would align with the long-range plan of high single digits to low double digits; normalized growth is expected beyond 2027.
FY2026 CAPEX guidance is €230M–€240M, or €215M–€225M net of customer contributions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Stevanato Group
- High-value product growth and U.S. expansion drive strong margins and long-term outlook.STVN
Morgan Stanley 24th Annual Global Healthcare Conference - Strong growth, rising margins, and innovation in biopharma solutions drive long-term value.STVNInvestor presentation
- Q2 2026 revenue up 8% with margin gains, led by high-value solutions and strategic divestiture.STVNQ2 2026
- Strong growth in high-value pharma solutions, capacity expansion, and global integration drive outlook.STVNJefferies London Healthcare Conference 2025
- High-value ready-to-fill products and innovation drive growth and margin expansion.STVNJefferies Global Healthcare Conference 2026
- High-value solutions and biologics drive robust growth, with expanding margins and global investments.STVNInvestor presentation
- Q1 2026 revenue rose 10% at constant currency, with margin gains and guidance reaffirmed.STVNQ1 2026
- Revenue up 2% in Q3 2024, but margins and profit pressured by higher costs and destocking.STVNQ3 2024
- Q1 2025 revenue up 9% to €256.6M, with margin and free cash flow gains; 2025 outlook reaffirmed.STVNQ1 2025
Next Stevanato Group earnings date
Q4 20265 Mar, 2027
Stevanato Group
Next Stevanato Group earnings date
Q4 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Stevanato Group S.p.A. is a global provider of containment, delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. The company specializes in the production of glass containers, such as vials, syringes, and cartridges, used for drug storage and delivery. In addition to its core manufacturing services, Stevanato offers integrated solutions that include drug delivery systems, assembly equipment, and analytical testing. Its products support a range of applications, including injectable drugs, biologics, and diagnostics, helping ensure the safe and effective administration of treatments. The company is headquartered in Piombino Dese, Italy, and its shares are listed on the NYSE.